BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 22, 2025
Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Pozen Licenses MT 300 Rights To Xcel In Deal Worth At Least $10M

Sep. 5, 2003
By Aaron Lorenzo

CAT Avoids Patent Fight, Enters Deal With Enzon And Micromet

Sep. 4, 2003
By Aaron Lorenzo

CAT Avoids Patent Fight, Enters Deal With Enzon And Micromet

Sep. 4, 2003
By Aaron Lorenzo

AVI Terminates Planned Buyout Of eXegenics As Offer Expires

Sep. 3, 2003
By Aaron Lorenzo
Another merger agreement has fallen apart for eXegenics Inc. For the second time in the past year, the Dallas-based company saw its plans dissolve about two months after initially reporting a decision to combine with another firm. The latest suitor to walk away, AVI BioPharma Inc., said an insufficient number of eXegenics shareholders agreed to the tender offer. (BioWorld Today)
Read More

AVI Terminates Planned Buyout Of eXegenics As Offer Expires

Sep. 3, 2003
By Aaron Lorenzo
Another merger agreement has fallen apart for eXegenics Inc. For the second time in the past year, the Dallas-based company saw its plans dissolve about two months after initially reporting a decision to combine with another firm. The latest suitor to walk away, AVI BioPharma Inc., said an insufficient number of eXegenics shareholders agreed to the tender offer. (BioWorld Today)
Read More

Explosions Hit Chiron In Wake Of Recent Animal Rights Protests

Sep. 2, 2003
By Aaron Lorenzo
Chiron Corp. was bombed last week in what may have been the latest and most violent offense in a string of harassment incidents brought by animal rights protesters. (BioWorld Today)
Read More

Explosions Hit Chiron In Wake Of Recent Animal Rights Protests

Sep. 2, 2003
By Aaron Lorenzo
Chiron Corp. was bombed last week in what may have been the latest and most violent offense in a string of harassment incidents brought by animal rights protesters. (BioWorld Today)
Read More

Berlex Planning Phase III Study Of Leukine In Crohn's Patients

Aug. 29, 2003
By Aaron Lorenzo

Berlex Planning Phase III Study Of Leukine In Crohn's Patients

Aug. 29, 2003
By Aaron Lorenzo

Nymox Raises $12M Privately To Provide Three Years' Cash

Aug. 28, 2003
By Aaron Lorenzo
Previous 1 2 … 174 175 176 177 178 179 180 181 182 … 237 238 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing